Literature DB >> 24503275

Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia.

Casey Cook1, Judy H Dunmore1, Melissa E Murray1, Kristyn Scheffel1, Nawsheen Shukoor1, Jimei Tong1, Monica Castanedes-Casey1, Virginia Phillips1, Linda Rousseau1, Michael S Penuliar1, Aishe Kurti1, Dennis W Dickson2, Leonard Petrucelli2, John D Fryer3.   

Abstract

Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is a neurodegenerative tauopathy caused by mutations in the tau gene (MAPT). Individuals with FTDP-17 have deficits in learning, memory, and language, in addition to personality and behavioral changes that are often characterized by a lack of social inhibition. Several transgenic mouse models expressing tau mutations have been tested extensively for memory or motor impairments, though reports of amygdala-dependent behaviors are lacking. To this end, we tested the rTg4510 mouse model on a behavioral battery that included amygdala-dependent tasks of exploration. As expected, rTg4510 mice exhibit profound impairments in hippocampal-dependent learning and memory tests, including contextual fear conditioning. However, rTg4510 mice also display an abnormal hyperexploratory phenotype in the open-field assay, elevated plus maze, light-dark exploration, and cued fear conditioning, indicative of amygdala dysfunction. Furthermore, significant tau burden is detected in the amygdala of both rTg4510 mice and human FTDP-17 patients, suggesting that the rTg4510 mouse model recapitulates the behavioral disturbances and neurodegeneration of the amygdala characteristic of FTDP-17.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amygdala; Frontotemporal dementia; Neurodegeneration; Tau; Tauopathy

Mesh:

Substances:

Year:  2013        PMID: 24503275      PMCID: PMC3992979          DOI: 10.1016/j.neurobiolaging.2013.12.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  29 in total

1.  Syndrome of Klüver and Bucy; reproduced in man by bilateral removal of the temporal lobes.

Authors:  H TERZIAN; G D ORE
Journal:  Neurology       Date:  1955-06       Impact factor: 9.910

2.  CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.

Authors:  Leonard Petrucelli; Dennis Dickson; Kathryn Kehoe; Julie Taylor; Heather Snyder; Andrew Grover; Michael De Lucia; Eileen McGowan; Jada Lewis; Guy Prihar; Jungsu Kim; Wolfgang H Dillmann; Susan E Browne; Alexis Hall; Richard Voellmy; Yoshio Tsuboi; Ted M Dawson; Benjamin Wolozin; John Hardy; Mike Hutton
Journal:  Hum Mol Genet       Date:  2004-02-12       Impact factor: 6.150

3.  Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Authors:  Zdenek Berger; Hanno Roder; Amanda Hanna; Aaron Carlson; Vijayaraghavan Rangachari; Mei Yue; Zbigniew Wszolek; Karen Ashe; Joshua Knight; Dennis Dickson; Cathy Andorfer; Terrone L Rosenberry; Jada Lewis; Mike Hutton; Christopher Janus
Journal:  J Neurosci       Date:  2007-04-04       Impact factor: 6.167

4.  Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22.

Authors:  M Baker; J B Kwok; S Kucera; R Crook; M Farrer; H Houlden; A Isaacs; S Lincoln; L Onstead; J Hardy; L Wittenberg; P Dodd; S Webb; N Hayward; T Tannenberg; A Andreadis; M Hallupp; P Schofield; F Dark; M Hutton
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

5.  Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.

Authors:  John C O'Leary; Qingyou Li; Paul Marinec; Laura J Blair; Erin E Congdon; Amelia G Johnson; Umesh K Jinwal; John Koren; Jeffrey R Jones; Clara Kraft; Melinda Peters; Jose F Abisambra; Karen E Duff; Edwin J Weeber; Jason E Gestwicki; Chad A Dickey
Journal:  Mol Neurodegener       Date:  2010-11-01       Impact factor: 14.195

6.  Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia.

Authors:  Nicholas J Janocko; Kevin A Brodersen; Alexandra I Soto-Ortolaza; Owen A Ross; Amanda M Liesinger; Ranjan Duara; Neill R Graff-Radford; Dennis W Dickson; Melissa E Murray
Journal:  Acta Neuropathol       Date:  2012-09-12       Impact factor: 17.088

7.  Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex.

Authors:  T Lynch; M Sano; K S Marder; K L Bell; N L Foster; R F Defendini; A A Sima; C Keohane; T G Nygaard; S Fahn
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

8.  Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17.

Authors:  Tomonori Kobayashi; Hideo Mori; Yasuyuki Okuma; Dennis W Dickson; Natalie Cookson; Yoshio Tsuboi; Yumiko Motoi; Ryota Tanaka; Nobuo Miyashita; Midori Anno; Hirotaro Narabayashi; Yoshikuni Mizuno
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

9.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures.

Authors:  Pablo D Perez; Gabrielle Hall; Tetsuya Kimura; Yan Ren; Rachel M Bailey; Jada Lewis; Marcelo Febo; Naruhiko Sahara
Journal:  Mol Neurodegener       Date:  2013-02-04       Impact factor: 14.195

View more
  23 in total

1.  Cornel Iridoid Glycoside Suppresses Hyperactivity Phenotype in rTg4510 Mice through Reducing Tau Pathology and Improving Synaptic Dysfunction.

Authors:  Deng-Lei Ma; Yi Luo; Rui Huang; Zi-Run Zhao; Li Zhang; Ya-Li Li; Qi Wang; Lin Li; Lan Zhang
Journal:  Curr Med Sci       Date:  2021-01-11

2.  Subacute ibuprofen treatment rescues the synaptic and cognitive deficits in advanced-aged mice.

Authors:  Justin T Rogers; Chia-Chen Liu; Na Zhao; Jian Wang; Travis Putzke; Longyu Yang; Mitsuru Shinohara; John D Fryer; Takahisa Kanekiyo; Guojun Bu
Journal:  Neurobiol Aging       Date:  2017-02-09       Impact factor: 4.673

3.  Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.

Authors:  Emily J Koller; Elsa Gonzalez De La Cruz; Timothy Machula; Kristen R Ibanez; Wen-Lang Lin; Tosha Williams; Cara J Riffe; Daniel Ryu; Kevin H Strang; Xuefei Liu; Christopher Janus; Todd E Golde; Dennis Dickson; Benoit I Giasson; Paramita Chakrabarty
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

4.  Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia.

Authors:  Sally Kelliny; Jing Xiong; Larisa Bobrovskaya; Xin-Fu Zhou
Journal:  Neurotox Res       Date:  2021-10-02       Impact factor: 3.911

5.  Personality Associations With Amyloid and Tau: Results From the Baltimore Longitudinal Study of Aging and Meta-analysis.

Authors:  Antonio Terracciano; Murat Bilgel; Damaris Aschwanden; Martina Luchetti; Yannick Stephan; Abhay R Moghekar; Dean F Wong; Luigi Ferrucci; Angelina R Sutin; Susan M Resnick
Journal:  Biol Psychiatry       Date:  2021-09-03       Impact factor: 12.810

6.  C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins.

Authors:  Yong-Jie Zhang; Tania F Gendron; Jonathan C Grima; Hiroki Sasaguri; Karen Jansen-West; Ya-Fei Xu; Rebecca B Katzman; Jennifer Gass; Melissa E Murray; Mitsuru Shinohara; Wen-Lang Lin; Aliesha Garrett; Jeannette N Stankowski; Lillian Daughrity; Jimei Tong; Emilie A Perkerson; Mei Yue; Jeannie Chew; Monica Castanedes-Casey; Aishe Kurti; Zizhao S Wang; Amanda M Liesinger; Jeremy D Baker; Jie Jiang; Clotilde Lagier-Tourenne; Dieter Edbauer; Don W Cleveland; Rosa Rademakers; Kevin B Boylan; Guojun Bu; Christopher D Link; Chad A Dickey; Jeffrey D Rothstein; Dennis W Dickson; John D Fryer; Leonard Petrucelli
Journal:  Nat Neurosci       Date:  2016-03-21       Impact factor: 24.884

7.  Metabolic changes over the course of aging in a mouse model of tau deposition.

Authors:  Aurélie Joly-Amado; Karisa S Serraneau; Milene Brownlow; Caralina Marín de Evsikova; John R Speakman; Marcia N Gordon; Dave Morgan
Journal:  Neurobiol Aging       Date:  2016-04-25       Impact factor: 4.673

8.  Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test.

Authors:  A E Arrant; A J Filiano; B A Warmus; A M Hall; E D Roberson
Journal:  Genes Brain Behav       Date:  2016-07       Impact factor: 3.449

9.  Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology.

Authors:  Shalini S Rao; Larissa Lago; Irene Volitakis; Jay J Shukla; Gawain McColl; David I Finkelstein; Paul A Adlard
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

10.  Differential accumulation of tau pathology between reciprocal F1 hybrids of rTg4510 mice.

Authors:  Daijiro Yanagisawa; Hamizah Shahirah Hamezah; Aslina Pahrudin Arrozi; Ikuo Tooyama
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.